AstraZeneca study shows lung cancer benefits offered by Tagrisso

AstraZeneca has announced the findings of a new clinical trial that demonstrate the benefits its drug Tagrisso can offer to certain lung cancer patients.

The phase III FLAURA trial was conducted to assess the safety and efficacy of the therapy in previously untreated patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer.

A statistically significant and clinically meaningful progression-free survival benefit was observed when using Tagrisso, with the drug performing better than the current first-line standard of care treatment.

The efficacy, safety and tolerability profiles for Tagrisso and the comparator drugs were all consistent with current knowledge. Further evaluation of the FLAURA data is ongoing, with full results to be presented at a forthcoming medical meeting.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "The strong results from the FLAURA trial are very exciting news for patients with EGFR mutation-positive non-small cell lung cancer, providing physicians with a potential new first-line treatment option to improve outcomes in this disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.